Last edition
News about Global Pharma
In a groundbreaking clinical study, Zaynich (Zidebactam/Cefepime, WCK 5222) showcased over 97 percent clinical efficacy in treating critically ill patients with carbapenem-resistant Gram-negative infections.
Global Pharma | 13/01/2025 | By Manvi | 611
Telix Pharmaceuticals has regained marketing and distribution rights for Scintimun from Curium Pharma, with a strategic agreement appointing Curium as its manufacturer.
Global Pharma | 13/01/2025 | By Manvi | 544
Synaffix Signs License Deal with Mitsubishi Tanabe Pharma for ADC Technology
Synaffix is responsible for the manufacturing of the components that are related to its proprietary technologies, and MTPC is responsible for the research, development, manufacturing and commercialization of the ADC.
Global Pharma | 13/01/2025 | By Aishwarya | 318
The newly approved funding will support a Phase 1b trial of TP-317 in ulcerative colitis patients to identify safe and efficient dosing.
Global Pharma | 13/01/2025 | By Aishwarya | 451
Gilead and LEO Pharma to Advance Development of Oral STAT6 Program
STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD, amongst many others.
Global Pharma | 13/01/2025 | By Aishwarya | 300
Sciwind Signs Global Licensing Deal with Verdiva for Metabolic Disease Portfolio
Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea.
Global Pharma | 13/01/2025 | By Aishwarya | 681
Windlas Biotech Receives GMP Certification for New Injectable Facility
Windlas Biotech Ltd. has received Good Manufacturing Practices (GMP) certification for its state-of-the-art injectable facility from the Food Safety and Drugs Administration Authority of Uttarakhand.
Global Pharma | 10/01/2025 | By Manvi | 1093
SN BioScience Secures IND Clearance from FDA for SNB-101
SN BioScience announced that its lead asset, SNB-101, has received Investigational New Drug (IND) clearance from the US FDA for a Phase 1b/2 clinical trial, marking a significant milestone in its journey toward early commercialisation as a treatment for Extensive Stage Small Cell Lung Cancer (ES-SCLC).
Global Pharma | 10/01/2025 | By Manvi | 690
Ventris Medical's Backpack Bone Graft Systems Secure FDA 510(k) Clearance
Backpack® represents a new class of biomaterials designed for the optimisation of cell proliferation and bone formation and is used in orthopedic and spinal fusion procedures.
Global Pharma | 10/01/2025 | By Abha | 476
American Injectables Secures FDA Approval
American Injectables, specialising in sterile injectables, has announced that it has received FDA approval.
Global Pharma | 10/01/2025 | By Abha | 502
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy